Compare Ginkgo Bioworks Holdings Inc (DNA) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Otis Worldwide Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Otis Worldwide Corp trades at $65.98 (market cap $25.17B). The key difference: Otis Worldwide Corp is far larger — about 33× Ginkgo Bioworks Holdings Inc's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Otis Worldwide Corp for 66 Days on average.
| DNA | OTIS | |
|---|---|---|
Market Cap | $763.64M | $25.17B |
Volume | 3,204,177 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $15.83 | $93.62 |
52-Week Low | $5.48 | $64.05 |
Typical Hold Time | 7 Days | 66 Days |
Enterprise Value | $865.59M | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Otis Worldwide trades at $66.14, up 0.61% today but near its 52-week low, with technical indicators showing bearish momentum. The company reported mixed Q2 2026 results, missing EPS estimates while maintaining strong service revenue growth. Recent CEO succession news and China market challenges create uncertainty, though analyst consensus remains positive with a $87 price target representing 31% upside potential.
The stock presents a value opportunity with reasonable P/E of 16.99 and P/S of 1.73, but faces margin pressure and execution risks. Service segment growth and modernization backlog provide stability, while weak equipment demand and China exposure remain headwinds. Institutional ownership shows mixed signals with recent buying and selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
